The UK and US have announced a major trade agreement that will maintain zero tariffs on UK drug products being sold in the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to boost spending on pharmaceuticals through the National Health Service (NHS). This commitment ensures that import taxes on these vital products will be held at zero for a period of the next three years.
This deal follows earlier statements to significantly raise import taxes on patented drug products, with potential rates discussed up to one hundred percent.
"This deal with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces much-needed balance to transatlantic drug exports," an announcement noted.
Economic Importance
Medicines are one of the the United Kingdom's biggest export categories to the US, which is by far the largest destination for leading UK drugmakers.
Export figures show that in the 12 months leading up to September, the UK exported pharmaceutical products valued at billions to the US. This amount accounted for 17.4% of all goods exports in that period.
"This deal protects jobs, increases investment and paves the way for the UK to establish itself as a international leader for medical research," a government official remarked.
Key NHS Changes
The pact involves several notable pledges from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to increase overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be limited at 15%. Previously, rebates were more than twenty percent.
Industry Background
The pact follows a long-running dispute between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
This friction were exacerbated by assertions that American customers were charged a premium for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or scrapped, while major expansions have been pledged toward projects in the United States.
A senior figure stated that the NHS needed to spend more on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the previous ten-year period.
